ClinicalTrials.gg

Program

HRS-9813

A development code. Also written as “HRS-9813 Capsule”, “HRS-9813 capsules” and “HRS-6209 in Combination with HRS-9813 and Letrozole”.

Its studies are mostly in Pulmonary Fibrosis · Breast Neoplasms · Idiopathic Pulmonary Fibrosis, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Aug 1, 20246 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine62 open or runningphase 2since Aug 1, 2024Jul 17, 2024Dec 2027phase 2 · NCT06555068
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-9813, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 17, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06514963 · 50 enrolled · China
  2. Aug 1, 2024Phase 2 study in Breast NeoplasmsNCT06555068 · 528 planned · China
  3. Feb 5, 2025Phase 1 study in Idiopathic Pulmonary FibrosisNCT06821464 · 45 enrolled · China
  4. Apr 15, 2025Phase 1 study in Pulmonary FibrosisNCT06939504 · 12 enrolled · China
  5. Sep 18, 2025Phase 2 study in IPF and PPFNCT07192939 · 270 planned · China
  6. Nov 13, 2025Phase 1 study in Pulmonary FibrosisNCT07229716 · 20 enrolled · China

Ahead

  1. Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06555068
  2. Jun 2028Primary completion: phase 2 study in IPF and PPFNCT07192939

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07229716Pulmonary Fibrosis · China1CompletedJun 18, 202620
NCT07192939IPF and PPF · China2RecruitingJun 2028270
NCT06939504Pulmonary Fibrosis · China1CompletedJun 3, 202512
NCT06821464Idiopathic Pulmonary Fibrosis · China1CompletedJul 27, 202545
NCT06555068Breast Neoplasms · China2RecruitingDec 2027528
NCT06514963Healthy Volunteers · China1CompletedJan 2, 202550

How it is read

Names in the registry

  • “HRS-9813”, 3 entries
  • “HRS-9813 Capsule”, 2 entries
  • “HRS-9813 capsules”, 2 entries
  • “HRS-6209 in Combination with HRS-9813 and Letrozole”, 1 entry
  • “HRS-6209 in Combination with HRS-9813 and HRS-8080”, 1 entry

Codes read as this program: HRS9813.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.